Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients

Acta Neurochir (Wien). 2012 Jan;154(1):87. doi: 10.1007/s00701-011-1196-x. Epub 2011 Oct 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Benzimidazoles / administration & dosage*
  • Benzimidazoles / adverse effects
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / epidemiology
  • Dabigatran
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Injections, Intravenous / methods
  • Risk Factors
  • Stroke / drug therapy*
  • Stroke / epidemiology
  • Tissue Plasminogen Activator / administration & dosage*
  • Tissue Plasminogen Activator / adverse effects
  • beta-Alanine / administration & dosage
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*

Substances

  • Anticoagulants
  • Benzimidazoles
  • Fibrinolytic Agents
  • beta-Alanine
  • Tissue Plasminogen Activator
  • Dabigatran